Announcements

  • All
  • Announcements 2009
  • Announcements 2010
  • Announcements 2011
  • Announcements 2012
  • Announcements 2017
  • Announcements 2018
  • Announcements 2019
  • Announcements 2020
  • Announcements 2021
  • Announcements 2022
  • Announcements 2024

Paiania, 1 December 2023 - Lavipharm S.A. announces, in accordance with Regulation 596/2014/EU, the signing of an asset purchase agreement with Boehringer Ingelheim International GmbH for the acquisition of two analgesic pharmaceutical products, Lonarid N® and Lonalgal®, for the markets of Greece and Cyprus with...

Paiania, 8 November 2023 - Lavipharm S.A. announces key financial figures for the nine-month period of 2023 and business developments during third quarter: Lavipharm Key Financial Figures Q3 2023  ...

Παιανία, 14 Ιουλίου 2023 – Η ανώνυμη εταιρεία με την επωνυμία «ΑΝΩΝΥΜΗ ΕΜΠΟΡΙΚΗ ΚΑΙ ΒΙΟΜΗΧΑΝΙΚΗ ΕΤΑΙΡΙΑ ΦΑΡΜΑΚΕΥΤΙΚΩΝ, ΧΗΜΙΚΩΝ ΚΑΙ ΚΑΛΛΥΝΤΙΚΩΝ ΠΡΟΪΟΝΤΩΝ LAVIPHARM A.E.» και τον διακριτικό τίτλο «LAVIPHARM AE» (εφεξής, η «Εταιρεία»), γνωστοποιεί στο επενδυτικό κοινό σύμφωνα με τις διατάξεις του Ν. 3556/2007 (άρθρο 3 παρ....

Peania, 6 July 2023 – Lavipharm’s (LAVI) Annual Shareholders Meeting was held today at the corporate headquarters in Peania. The meeting was completed with the necessary quorum, as 33 shareholders participated representing a percentage 70.78%. The General Assembly began its proceedings with the welcome speech of...

Vicky D. Kefalas joins Lavipharm’s Board of Directors Establishment of a long-term incentive plan Peania, 26 May 2023 – Lavipharm’s Extraordinary Shareholders Meeting, held at today at the corporate headquarters, decided in favor of the election of a new member of the Board of Directors and the...

Peania, 16 May 2023 – Lavipharm today presented its key financial results and activities to the Hellenic Fund and Asset Management Association. The presentation took place in the context of the Annual Analyst Update as per the Company’s 2023 Financial Calendar and was held at...

Paiania, 12 May 2023 – Lavipharm S.A., according to the provisions of article 19 of the European Regulation No 596/2014 and following relevant notification, announces that Mr. Thomas Tseronis, Head of Sales Rx, sold 35.434 Lavipharm common shares, amounting in total to €15.732,7....

Paiania, 4 May 2023 – Group Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) increased by 34% during the first quarter of 2023 and amounted to €2.46 million compared to €1.84 million during the relevant period of the previous year. Lavipharm Key Financial Figues Q1 2023...

Paiania, 27 April 2023 - Lavipharm S.A, pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, and as part of providing accurate and timely information to the investment community, announces the amended Financial Calendar of 2023. The amendment refers to the Analysts’...

Paiania, 28 March 2023 – Lavipharm S.A., according to the provisions of article 19 of the European Regulation No 596/2014 and the Regulation of the Athens Exchange, announces the appointment of Mr. Evangelos Paterakis as Chief Accountant replacing Mr. Panagiotis Pavlou, who is retiring.   ###...